{"text": "filing for 8 k press news current report has been made with the sec bmy celg ri bmy ri bristol myers squibb co"}
{"text": "3 azn cotadutide ph2a trial in f1 f3 nafld nash primary completion may 10 4 enta fxr agonist edp305 ph2b results delayed to 3q21 5 also still waiting for bmy fgf21 pegbelfermin ph2b results in f3 and cirrhotic nash primary completion was september 2020 akro etnb"}
{"text": "what really mattered with editas medicine s q1 update stocks edit bmy"}
{"text": "btw my comment wasnt really intended to be about mrk vs bmy on io rather commentary on nktr pr entirely pivot to bempegaldesleukin plus pembrolizumab hardly mention anything about nivolumab it is hard for others to get my intention sometimes when one is so defensive"}
{"text": "form 8 k submission of matters to a vote of security ho the annual meeting of the company was held on may 4 2021 shareholders voted on the matters set forth below bmy"}
{"text": "bmy valuation ratios vs time trailing metrics valuationratios bmy"}
